MYCOPLASM S 360 Mycophenolate sodium (360mg) Mycophenolate sodium is an immunosuppressive medication used to prevent the rejection of organ transplants, particularly kidney transplants. It is a prodrug of mycophenolic acid and belongs to a class of drugs known as mycophenolic acid derivatives. Here are some key points about mycophenolate sodium: Indications: Mycophenolate sodium is primarily used in combination with other immunosuppressive medications to prevent rejection in patients who have received kidney transplants. Mechanism of Action: Mycophenolate sodium is a prodrug that is converted to mycophenolic acid in the body. Mycophenolic acid inhibits the proliferation of immune cells, particularly T and B lymphocytes, by blocking the enzyme inosine monophosphate dehydrogenase. This enzyme is involved in the synthesis of guanosine nucleotides, which are necessary for DNA replication. Dosage: The dosage of mycophenolate sodium can vary based on the specific transplant protocol and individual patient factors. It is typically taken orally and may be administered with or without food. Administration: Mycophenolate sodium tablets should be swallowed whole and not crushed or chewed. The medication is usually taken twice daily. Monitoring: Patients taking mycophenolate sodium are regularly monitored for signs of rejection, as well as for potential side effects. Blood tests, including complete blood counts and assessments of kidney function, are commonly performed. Common Side Effects: Common side effects of mycophenolate sodium include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain. These side effects may improve with time or can sometimes be managed by adjusting the dosage or taking the medication with food. Contraindications and Precautions: Mycophenolate sodium is contraindicated in individuals with known hypersensitivity to the drug. It may also pose risks to the fetus during pregnancy, and adequate contraception is advised for both men and women during treatment. Pregnancy and Breastfeeding: Mycophenolate sodium is associated with a risk of congenital malformations and spontaneous abortions if taken during pregnancy. Women of childbearing potential should use reliable contraception during treatment and for a period after discontinuation. Breastfeeding is not recommended during mycophenolate sodium therapy. It's crucial for individuals taking mycophenolate sodium to adhere to their prescribed dosage and schedule. Any signs of rejection or adverse effects should be promptly reported to the healthcare provider. The use of immunosuppressive medications, including mycophenolate sodium, requires close monitoring by healthcare professionals to balance the prevention of rejection with minimizing potential side effects. Steris Healthcare Pvt. Ltd. is a Leading Pharmaceutical Company in India. Established in the year of May 2018. We have 750+ Products & 16+ Super Specialty Segments. Every week we have a new product in our portfolio. In Last 4 years we are dealing in Chronic Therapy and in 4 years we grow by 200% Annually, because we deal in high quality medicine. Steris medicine manufactures at WHO-GMP Approved Plants & We have Legal manufacturing contracts with all leading manufacturers of India. Today we have 1000+ Business Franchise Partners in PAN India. Steris's medicine supply in India's Top or Reputed Hospitals, Pharmacy, Government use or Railway use. Grow with a similar pace with the STERIS. Be first to launch like us. For further information please contact: info@sterispharma.com order now: https://www.sterisonline.com/product/mycoplasm-s-360-133670